Omnicare — Investor Day (December 2011)
133 slides from Omnicare's investor day presentation, Dec 9, 2011
Slide 1: Omnicare Analyst Day 2011
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-looking Statements Certain of the statements made today and listed within the following presentation slides are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are
Slide 3: John Figueroa, Chief Executive Officer
John Figueroa Chief Executive Officer
Slide 4: Management Presenters
John Workman Jeff Stamps Nitin Sahney President and Chief Financial Officer Executive Vice President and President LTC Operations Executive Vice President and President Specialty Care Group John Figueroa Chief Executive Officer Management Presenters
Slide 5: Today's Objectives
Today’s Objectives
Slide 6: Today's Objectives
Today’s Objectives • Strategic overview • Financial review • Greater visibility – Long-Term Care – Specialty Care Group • Additional metrics for greater transparency • Future growth opportunities • Question & Answer session
Slide 7: Creating Value
Creating Value
Slide 8: Omnicare's Fundamental Objective
Cash Flow Generation Specialty Care Group Value Creation Omnicare’s Fundamental Objective Focused on Growth and Creating Value
Slide 9: 30-Year Evolution
30-Year Evolution
Slide 10: Omnicare's 30-Year Evolution: A Different Company Today
Acute Care Facilities/Hospitals Omnicare’s 30-Year Evolution A Different Company Today Omnicare today is a company that spans the healthcare continuum, providing services designed to improve outcomes at the lowest possible cost.
Slide 11: Omnicare's 30-Year Evolution: A Different Company Today
Skilled Nursing Facilities Patients Other Institutional Settings Caregivers Physicians Nurses Manufacturers Omnicare’s 30-Year Evolution A Different Company Today Omnicare today is a company that spans the healthcare continuum, providing services designed to improve outcomes at the lowest possible c
Slide 12: Timeline of Events
1988 First investment in Long Term Care Omnicare sells CRO business, announces tender offer for PharMerica 2005 Omnicare introduces Geriatric Pharmaceutical Care Guidelines ® 1989 Omnicare sells Hospital business 2010 Omnicare begins cultural and strategic repositioning 2003 Omnicare named to the FO
Slide 13: Sizing Up the Business
Omnicare’s 30-Year Evolution Sizing Up the Business More transparency into Specialty Care Group to be provided in 4Q11
Slide 14: Our Employees are Foundational to Our Success
Omnicare’s 30-Year Evolution Our Employees are Foundational to Our Success • Clinical expertise provides for differentiated offering • Localized services require customer-focused teams • Investments made to better align employee interests • Launch of core values to continue cultural transformation –
Slide 15: Industry Growth Dynamics
Industry Growth Dynamics
Slide 16: Aging Population Shaping US Healthcare System
Demographic Trends Aging Population Shaping US Healthcare System Source: U.S. Census Bureau Seniors generally have higher pharmaceutical utilization rates, and adherence to medication is essential to lowering overall healthcare costs
Slide 17: Continued Rise of Generics, Specialty Drugs
Pharmaceutical Market Dynamics Continued Rise of Generics, Specialty Drugs 1. Source: IMS - Total US Pharma Prescriptions Omnicare positioned well to capitalize on both growing markets; generics and specialty. Forecasted Pharmaceutical Developments (1) by Drug Type
Slide 18: Continued Rise in New Generic Introductions
Pharmaceutical Market Dynamics Continued Rise in New Generic Introductions 2. Omnicare Source: Assumptions based on Omnicare data and OCR projected inflation rates Omnicare’s speed to generic conversion benefits customers, and will be increasingly critical as new generics become available.
Slide 19: Typical Life Cycle of Nonexclusive Generic Drug
Pharmaceutical Market Dynamics Typical Life Cycle of Nonexclusive Generic Drug NOTE: Graph is for illustrative purposes only. Not representative of every generic drug, as each generic drug has unique characteristics. Lowers sales but stronger gross profit margin and dollars over time.
Slide 20: Focus on Three Core Operating Objectives
Transitioning to an Operations-Driven Company Focus on Three Core Operating Objectives • Establish consistent organic growth in our Long-Term Care Group • Reposition Specialty Care Group for an elevated level of growth • Create more standardization across the company
Slide 21: Establishing Consistent Organic Growth in LTC
Transitioning to an Operations-Driven Company Establishing Consistent Organic Growth in LTC • Focus on customer retention – Revamp corporate culture, increase employee engagement – Align incentive programs with customer service to improve retention – Reshape the organization to bring it closer to th
Slide 22: Creating More Standardization
Transitioning to an Operations-Driven Company Creating More Standardization • Operating efficiencies – Benchmarking – Insourcing – Six Sigma-Focused Culture • Technological improvements – ONE System – Automation – Customer-facing technology – Medication availability Standardization opportunities exp
Slide 23: 3Q11 YTD Net Organic Bed Loss Lower
3Q11 YTD net organic bed loss is 49.5% lower than 3Q10 YTD Transitioning to an Operations-Driven Company Establishing Consistent Organic Growth in LTC 43.2% better than 2010
Slide 24: Repositioning Specialty Care Group for Elevated Growth
Transitioning to an Operations-Driven Company Repositioning Specialty Care Group for Elevated Growth
Slide 25: Repositioning Specialty Care Group for Elevated Growth
Transitioning to an Operations-Driven Company Repositioning Specialty Care Group for Elevated Growth Omnicare specialty care growth has been robust…and opportunities exist to further accelerate growth through: • Continued improvements to the organizational structure – Investments made in manufacture
Slide 26: Acquisition Program
Acquisition Program Opportunities to Leverage Infrastructure • Omnicare’s scalable platform makes LTC acquisitions attractive – Leverage synergies through direct purchasing of generics – Utilize hub-and-spoke network and automation/technology platforms – Improvements in customer retention efforts lo
Slide 27: Omnicare's Fundamental Objective
Cash Flow Generation Specialty Care Group Value Creation Omnicare’s Fundamental Objective Focused on Growth and Creating Value
Slide 28: Slide 28
Slide 29: John L. Workman, President & Chief Financial Officer
John L. Workman President & Chief Financial Officer
Slide 30: Financial Overview
Financial Overview
Slide 31: Operating Performance
Operating Performance Sequential Progression Five Quarter Trend (1) (in millions, except percentage data) 1. Excludes discontinued operations.
Slide 32: Financial Performance
Financial Performance Sequential Progression Five Quarter Trend (1)(2) (in $ millions, except per share data) 2. Excludes special items. A reconciliation of certain non-GAAP information is available on Omnicare’s Web site under ‘Supplemental Financial Information’ from the ‘Investors’ page.
Slide 33: Financial and Operational Highlights
. Financial and Operational Highlights Third Quarter 2011 Highlights • Gross profit increased 2.9% sequentially to $346.1M on 0.7% decrease in sales – Gross margin sequentially higher by 79 bps to 22.4%, reflecting higher generic dispensing rates • Cash flows from continuing operations of $167.1M in
Slide 34: Focus on Cash Flow: Year-to-Date 2011
Focus on Cash Flow Year-to-Date 2011 Performance 1. Excludes discontinued operations. 3Q11 YTD cash flow from continuing operations 66.4% higher than 3Q10 YTD
Slide 35: High Quality of Earnings
Focus on Cash Flow High Quality of Earnings A significant amount of Omnicare’s earnings is converted into cash flow 1. Free cash flow = cash flow from continuing operations less capital expenditures and dividends paid. Free cash flow does not fully reflect the ability to freely deploy cash as it doe
Slide 36: Cash Flow Drives Substantial Value
Focus on Cash Flow Cash Flow Drives Substantial Value • Highly compelling financial attribute is cash flow generation capability – High quality of earnings – Creates flexibility for capital allocation initiatives • Substantial value exists below the EBITDA line – Significant amount of ongoing intang
Slide 37: Substantial Long Term Value Exists Below the EBITDA Line
Focus on Cash Flow Substantial Long Term Value Exists Below the EBITDA Line These items carry a weighted average life of over 9 years if the company were to make no additional acquisitions
Slide 38: Moving to Cash-Based EPS Reporting
Beginning in 2012, Omnicare will report adjusted earnings excluding intangible asset amortization While adding back: Goodwill amortization tax deduction, and Contingent convertible debenture interest tax deduction Focus on Cash Flow Moving to Cash-Based EPS Reporting
Slide 39: Reasons Behind Moving to Cash-Based EPS Reporting
Focus on Cash Flow Reasons Behind Moving to Cash-Based EPS Reporting • Increased transparency – Clarifies some of the drivers behind Omnicare’s strong cash flows – Narrows the gap between Omnicare’s adjusted earnings and cash flows • Sustainable benefit over the long-term – Weighted average life of
Slide 40: Pro Forma Results
3Q11 YTD (4) Contingent Convertible Debenture Interest - after tax 2,125 (6) Total Additional Special Items - after tax $ 58,192 (7) Diluted Adjusted EPS (2) $ 1.55 (8) Cash EPS Adjustments $ 0.51 (9) Diluted Adjusted Cash EPS (2) $ 2.06 (10) Effective Tax Rate 37.5% (11) Dil. Avg. Shares Outstandin
Slide 41: Putting the Robust Cash Flows to Work
Capital Allocation Putting the Robust Cash Flows to Work
Slide 42: Putting the Robust Cash Flows to Work
Capital Allocation Putting the Robust Cash Flows to Work (1)(2) 1. Excluding potential acquisition of PharMerica 2. Cumulative % Returned = (Dividends Paid + Share Repurchases) / 12/31/10 Market Capitalization of $2,961.0 million Third quarter year-to-date capital returned to shareholders increased
Slide 43: Capital Structure
1. Assumes convertible debentures due 2035 are put to the company in 2015 with related tax recapture included and debt amounts shown are exclusive of unamortized debt discount. Capital Structure Goal is to spread out maturities to limit refinancing risk
Slide 44: Longer-Term Targets
Target • Adjusted Diluted EPS Double digit three-year CAGR for the year ending 2013 • Cash Flow from Operations $400 - $500 million annually • Capital Returned to Shareholders Approximately 25% per year (2) • Capital Structure Focus on continued debt reduction, management of maturity schedules Finan
Slide 45: Forward-Looking Major Drivers
Major Drivers 2012 2013 2014 • Brand-to-generic Positive Neutral Neutral • Organic Growth - Long-Term Care Neutral Positive Positive • Reimbursement Negative Negative Negative • Specialty Care (2) Positive Positive Positive • ONE System Neutral Positive Positive • Standardization Initiatives Neutral
Slide 46: ONE System
ONE System
Slide 47: Efficiency-Driving Infrastructure Enhancement
Efficiency-Driving Infrastructure Enhancement • Implementing plans to modernize our Pharmacy and Billing System – Currently utilizing multiple dispensing systems running technology that is not state of the art – Not fully integrated with LTC product lines and financial systems – Specialty Care Group
Slide 48: Anticipated Operational Benefits
Anticipated Operational Benefits • Improved customer service through customer-facing technology – Integration from the facility to the pharmacy • Improved technology foundation – Pharmacy automation – On-site facility automation – Communication with payors • Improved compliance performance • Improve
Slide 49: Implementation Releases and Schedules
Implementation Releases and Schedules
Slide 50: Anticipated Financial Benefits and Return on Investment
Anticipated Financial Benefits and Return on Investment • Cost Benefits – No longer supporting 2 disparate systems – Fewer resources (headcount) in collections, dispute resolution – Executive information needs “main streamed” • Integrated with CPOE efforts to create efficiencies for lost revenue and
Slide 51: Slide 51
Slide 52: Jeff Stamps, President LTC Operations
Jeff Stamps Executive Vice President and President LTC Operations
Slide 53: LTC Pharmacy
LTC Pharmacy
Slide 54: By the Numbers
By the Numbers
Slide 55: Long-Term Care Pharmacy: By the Numbers
Long-Term Care Pharmacy By the Numbers
Slide 56: Long-Term Care Pharmacy: By the Numbers
Long-Term Care Pharmacy By the Numbers Our customer base is very fragmented with our largest facility customer representing only 2.6% of Long-Term Care revenue 1. Based on 3Q11 YTD results
Slide 57: Operating Model
Operating Model
Slide 58: Typical Prescription Dispensing Cycle
Long-Term Care Pharmacy Typical Prescription Dispensing Cycle
Slide 59: The Omnicare Advantage
The Omnicare Advantage
Slide 60: COST Management Equates to Customer Success
Omnicare’s Offering Revolves Around Value Creation COST Management Equates to Customer Success • eRefill • Managed care exclusions • Discharge to home • Returns • Split billing • Infusion • Survey preparedness • Customer defined • Omniview admissions review • Omniview paperless invoice • Omniview ma
Slide 61: Clinical, Operational, Specialty, Technology
Operationalll Specialty [J Technology
Slide 62: Omnicare's Clinical Organization
Omnicare’s Clinical Organization Robust Infrastructure in Place to Improve Patient Outcomes
Slide 63: Clinical Processes & Programs
Clinical Processes & Programs Clinical Tools Designed to Create Value for Customers
Slide 64: Clinical Program Content and Design
Clinical Program Content and Design • Geriatric Pharmaceutical Care Guidelines ® – Clinical ratings determined by Philadelphia College of Pharmacy – Endorsed by American Geriatrics Society • Health management programs are evidenced-based – Chief Clinical Officer • Established policies and procedures
Slide 65: Generic Drug Efficiencies
Generic Drug Efficiencies Speed-to-Generic Conversion Drives Value Omnicare’s customers have realized over $200 million in savings from generics launched for the trailing four quarters 1. Source: Omnicare and IMS data for Aricept, Levaquin, Xalatan, Zyprexa and Zyprexa Zydis
Slide 66: Slide 66
Slide 67: Operationally Driven Services
Pharmacy quality assurance audit Service charges adhere with contract terms Contract non-covered rules are followed RxClaim Adherence Non-covered charge control Credit memo Electronic invoicing and timeliness of bills to customer Medical records review New transition / start up support Educational i
Slide 68: Co-Marketing Opportunities
Marketing Brochures Infusion Program Discharge Programs Health Fairs Medical Screenings Omnicare-at-Home Operationally Driven Services Co-Marketing Opportunities Programs Designed to Assist with Census Development
Slide 69: Clinical, Operational
F Clinical Operational
Slide 70: Specialty Programs
Specialty Programs • Infusion • Survey preparedness • Customer defined • Leveraging Specialty Care Group assets Improving the quality of services provided to enhance patient care
Slide 71: Clinical, Operational, Technology
F Cinical Operational “Technology
Slide 72: Pharmacy Automation Video
Pharmacy Automation Video
Slide 73: Technology Strategy
Technology Strategy Deployment of Automation and Customer-Facing Technology • Develop and implement new technology for Pharmacy and In-Facility solutions that provides the following benefits: – Highest accuracy and quality with a validate-able process – A streamlined process to improve service – Red
Slide 74: Leading Technology Initiatives
A proprietary robotic dispensing process for card and box products 18 ALV systems are currently in operation with plan to add systems in 2012 Combines the pick, label print & apply, verification and sorting steps into one function Currently in pilot with roll-out commencing in mid-2012 Most efficien
Slide 75: Leading Technology Initiatives
Technology Tools Leading Technology Initiatives • As we expand our current base of validate-able technology with additional ALV units and planned ULV units, the percentage of scripts automated is expected to increase dramatically Technology initiatives expected to be a driver of cost savings, retent
Slide 76: Omniview
Classic Omniview OmniviewDr MyOmniview Omniview ™ Omnicare’s secure web-based worksite for customer facilities , prescribers and patients
Slide 77: Classic Omniview
Billing, Claims Management, Census Drug Info, Geriatric Pharmaceutical Care Guidelines ®, P&Ps, Medicare Part D Drug Spend, Utilization, Formulary Consultant Pharmacist Reviews, Health Management, IV Therapy Protocols Barcode scan processing refills, Returns (where permissible), Drug destruction (wh
Slide 78: Omniview Usage Increasing Among Customer Base
Customer-Facing Technologies Omniview™ Usage Increasing Among Customer Base
Slide 79: OmniviewDr
Customer-Facing Technologies OmniviewDr Profile Allows you to update information related to your profile. Medication Regimen Review Allows you to review and respond to patient-specific comments posted by the Omnicare consultant pharmacist Health Record Allows you or your staff to view your SNF, ALF
Slide 80: Omniview Video
Omniview TM Video
Slide 81: MyOmniview
Customer-Facing Technologies Enhance Connectivity MyOmniview
Slide 82: Establish Consistent Organic Growth
Establish Consistent Organic Growth
Slide 83: Focus on Customer Retention
Establish Consistent Organic Growth Focus on Customer Retention • Initiatives designed to improve the customer experience – Revamp corporate culture, increase employee engagement – Align incentive programs with customer service to improve retention – Reshape the organization to bring it closer to th
Slide 84: Focus on Customer Retention
Establish Consistent Organic Growth Focus on Customer Retention Customer response to service enhancement initiatives has been favorable.
Slide 85: Sales and Marketing Developments
Establish Consistent Organic Growth Sales and Marketing Developments • Initiatives designed to accelerate sales results – Revamped commission programs – Reorganization of sales force - improve coordination of selling process – Size of sales force doubled since the start of 2011 – Investments in sale
Slide 86: Sales and Service Initiatives Gaining Traction in 2011
3Q11 YTD net organic bed loss is 49.5% lower than 3Q10 YTD Establish Consistent Organic Growth Sales and Service Initiatives Gaining Traction in 2011 43.2% better than 2010
Slide 87: Growth Opportunities Beyond Skilled Nursing Facilities
Establish Consistent Organic Growth Growth Opportunities Beyond Skilled Nursing Facilities (1) 1. Based on market analyses performed by the company
Slide 88: Using the Omnicare Advantage to Drive Growth
Value Creation Using the Omnicare Advantage to Drive Growth Through The Omnicare Advantage , we believe we will establish consistent organic growth in Long-Term Care Pharmacy.
Slide 89: Slide 89
Slide 90: Nitin Sahney, President Specialty Care Group
Nitin Sahney Executive Vice President and President Specialty Care Group
Slide 91: Specialty Care Group
Specialty Care Group
Slide 92: By the Numbers
By the Numbers
Slide 93: Specialty Care Group: By the Numbers
Specialty Care Group By the Numbers
Slide 94: Using the Omnicare Advantage to Create Value
Solution Driven Manufacturer Centric Value Creation Using the Omnicare Advantage to Create Value
Slide 95: Specialty Market
Specialty Market
Slide 96: What is Specialty?
What is Specialty? • Specialty product characteristics – Annual cost of therapy ($25,000 to $150,000 per year) – Patient population (ranging from hundreds to 250,000) – Route of administration (frequently injected or infused) – Chronic disease states – All branded products, typically injectable • Ra
Slide 97: Specialty Therapeutic Categories
Specialty Therapeutic Categories • Rheumatoid Arthritis – Enbrel – Humira • Multiple Sclerosis – Avonex – Copaxone – Betaseron • Onocology – Revlimid – Gleevec • Growth Hormones – Norditripin – Nutropin 1. Medco data
Slide 98: Framing the Specialty Market
Framing the Specialty Market 1. Source: EvaluatePharma; World Preview 2016 Specialty drug market growing four times as fast as the traditional drug market with annual growth rates ranging from 15-20% Pharmaceutical Market Share (1) by Drug Type
Slide 99: Specialty Products Face Unique Challenges
Small Patient Populations Complex Supply Chain Clinical Support Insurance Cost Regulatory Monitoring Specialty Products Face Unique Challenges Framing the Specialty Market
Slide 100: Omnicare's Specialty Opportunity
Omnicare’s Specialty Opportunity
Slide 101: Seizing the Opportunity
Seizing the Opportunity
Slide 102: Value Creation through Unique Solutions
Patient Co-Pay Services Specialty Pharmacy Support HUB Services Value Creation through Unique Solutions Undifferentiated Differentiated Commoditized Premium
Slide 103: Our Solutions Create Value
The SCG Support Products from Phase III through Commercialization Our Solutions Create Value The Physicians Smooth Initiation of therapy Build brand loyalty Reduce staff time The Manufacturer Retain and increase market share Deliver brand promise Differentiation from competition The Patient Remove b
Slide 104: Operational Platforms and Revenue Models
Manufacturer Fee for Service Model Manufacturer owns the product Third Party Payers Buy/Sell Model Hospices Per Diem Model SCG owns the product End of Life Care Operational Platforms Brand Support Services Third Party Logistics PAP & Consigned Pharmacy Specialty Pharmacy Customer Revenue Product
Slide 105: Proven Success
Proven Success
Slide 106: A Case Study: Consolidation of Services
A Case Study Consolidation of Services Growth Hormone • Seven (7) products in the market before our launch • Brand differentiation created through: – Product’s injection device – Manufacturer’s patient/physician support center
Slide 107: A Case Study: Consolidation of Services
A Case Study Consolidation of Services • Client’s product was trailing in market share • Support services were disjointed and offered through separate organizations
Slide 108: A Case Study: Consolidation of Services
A Case Study Consolidation of Services • Consolidation of services into a single organization - control of messaging • Partner with company solely focused on the success of the program/product
Slide 109: A Case Study: Consolidation of Services
A Case Study Consolidation of Services • Contributes to successful product launch • Support program was rated number one in blinded study in 2010 by 26% over competitive programs • Improved adherence and patient care
Slide 110: Omnicare Specialty Care Group and Service Providers
Omnicare Specialty Care Group ACS Brand Support SP Rx Fulfillment excelleRx Hospice PBM Plus Brand Support RxCrossroads Brand Support Third Party Logistics PAP/Consigned Rx Service Providers Covance Public Brand Support Parexel Public Brand Support Amerisource Bergen (ICS, Lash, Theracom) Public Bra
Slide 111: Repositioning for Elevated Growth
Repositioning for Elevated Growth
Slide 112: The First Year: Laying the Foundation for Growth
Nov 2010 Dec 2010 Jan 2011 Feb 2011 Mar 2011 Apr 2011 May 2011 Jun 2011 Jul 2011 Aug 2011 Sept 2011 Oct 2011 Nov 2011 The First Year Laying the Foundation for Growth Group Formed EVP/President Hired SVP - Operations SCG 11/1/2011-1/28/11 Evaluation of Existing SP Operations 2/5/11 VP Finance for ACS
Slide 113: The First Year
The First Year • Supporting manufacturers – Managed over $1B in commercial inventory annually • 99.97% inventory accuracy – Shipped over 19 million units in the past year • 99.97% shipment accuracy – Stored and managed over 1 million liters of plasma on a weekly basis • Market leader in plasma suppl
Slide 114: The First Year
The First Year Group poised for solid organic growth • Industry experiencing top-line growth of 15%-20% • Focus on client retention – No manufacturer client losses in the past year – Achieved organic growth with current partners • Winning new business – Awarded and transitioned business from direct
Slide 115: The First Year
Implementing program leveraging multiple platforms of the group Used to support 2011 growth from transition of business from competitors Currently at 25% capacity for growth Industry expertise for solution development The First Year
Slide 116: Financial Accomplishments Since Reorganization
The First Year Financial Accomplishments Since Reorganization 1. Pro-Forma, subject to change 2. Excludes any corporate allocation, therefore not reflective of pure stand-alone business
Slide 117: SCG Revenue
SCG Revenue YTD 9/30/11 Payor Mix Revenue by Service
Slide 118: Looking Ahead
Looking Ahead
Slide 119: Looking Ahead
Looking Ahead • Leverage expertise for organic growth in key therapeutic categories – Oncology – Auto-Immune – Infectious Disease – Endocrinology – Blood Disorders • Integrated solutions create growth across platforms – Brand support • HUB programs • Reimbursement • Co-pay assistance – Third party l
Slide 120: Using the Omnicare Advantage to Create Value
Solution Driven Manufacturer Centric Value Creation Using the Omnicare Advantage to Create Value
Slide 121: Slide 121
Slide 122: John Figueroa, Chief Executive Officer
John Figueroa Chief Executive Officer
Slide 123: Looking Ahead
Looking Ahead
Slide 124: New Disclosures for Greater Transparency
New Disclosures for Greater Transparency 1. Initial guidance for 2012 will be presented both ways.
Slide 125: Compelling Avenues for Growth
Compelling Avenues for Growth
Slide 126: Efficient Capital Deployment to Augment Growth
Efficient Capital Deployment to Augment Growth Initiatives Robust cash flow generation is expected to be redeployed toward growth drivers
Slide 127: Goal to Generate Consistent Double-Digit Adjusted EPS Growth
Goal to Generate Consistent Double-Digit Adjusted EPS Growth 1. Not intended to represent expectations for any given year.
Slide 128: PharMerica Offer
PharMerica Offer • PharMerica offer – Believe PharMerica to be an excellent fit – Complementary business would enable combined company to benefit from enhanced scale, provide a broader array of service offerings – Consistent with the country’s ongoing efforts to lower healthcare costs – The time for
Slide 129: Omnicare's Efforts to Solve the Healthcare Cost Dilemma
Efficiency Improvements Greater Adherence Patient Assistance Programs Efficiency Improvements Technological Investments Efficiency Improvements Third Party Logistics Lower Drug Costs Disease Management Greater Adherence Brand Support Efficiency Improvements Omniview Lower Drug Costs Generic Drugs Lo
Slide 130: Omnicare's Fundamental Objective
Cash Flow Generation Specialty Care Group Value Creation Omnicare’s Fundamental Objective Focused on Growth and Creating Value
Slide 131: Senior Management
Senior Management
Slide 132: Management Team
Rocky Kraft SVP, Finance Bob Dries SVP, Operations Finance Group Beth Kinerk SVP, Sales and Customer Development Tracy Finn EVP, Strategic Planning and Development Aly Kayne SVP, General Counsel Gary Erwin SVP, Professional Services Tim Hopkins SVP, Trade Relations Tim Canning SVP, Marketing Dan Mal
Slide 133: Slide 133